Publication details
Erectile Dysfunction Treatment Using Focused Linear Low-Intensity Extracorporeal Shockwaves: Single-Blind, Sham-Controlled, Randomized Clinical Trial
| Authors | |
|---|---|
| Year of publication | 2020 |
| Type | Article in Periodical |
| Magazine / Source | Urologia Internationalis |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.karger.com/Article/FullText/504788 |
| Doi | http://dx.doi.org/10.1159/000504788 |
| Keywords | Erectile dysfunction; Cardiovascular disease; Low-intensity extracorporeal shockwave; Phosphodiesterase-5 inhibitors |
| Description | Introduction:Low-intensity extracorporeal shock wave therapy (Li-ESWT) is a new treatment modality for erectile dysfunction (ED). Our aim was to evaluate the treatment outcome of Li-ESWT for ED in single-blind, placebo controlled, randomized clinical trial.Methods:Sixty patients were randomized into 2 age-matched groups: Group A - treatment and Group B - placebo. Treatment consisted of 4 sessions on the PiezoWave2 unit (R. Wolf and ELvation Medical). Effectiveness was assessed according to the International Index of Erectile Function 5 (IIEF-5), Erectile Hardness Score (EHS), questions 2 and 3 of the Sexual Encounter Profile (SEP 2, SEP 3), and Global Assessment Question (GAQ) scores at baseline and 4 and 12 weeks after treatment. We evaluated patient's and partner's subjective satisfaction.Results:A statistically significant difference between the groups was found at 4 and 12 weeks after treatment with regard to the quality of erection as measured by the IIEF-5 (p= 0.049 andp< 0.001, respectively), the EHS after week 12 (p< 0.001), an increase in the EHS after 4 and 12 weeks (p= 0.030 andp< 0.001, respectively), after 12 weeks in GAQ (p< 0.001), SEP 2 (p= 0.05), SEP 3 (p< 0.001), and patient's satisfaction (p< 0.001) and partner's satisfaction (p< 0.001).Conclusions:The randomized single-blind study confirms that Li-ESWT significantly improves erectile function. |